Multiple Sclerosis

There are 2 approaches for treating multiple sclerosis (MS) and the DELIVER-MS study is the first to see which approach works better, said Daniel Ontaneda, MD, a neurologist at the Cleveland Clinic.

In the past 5 decades, there has been a steady rise in the prevalence of multiple sclerosis (MS), according to estimates using a validated algorithm across 5 large US administrative health claims data sets. The research was published in Neurology.

Women with multiple sclerosis (MS) who give birth do not face an increased risk of relapses postpartum. New research being presented in May at the American Academy of Neurology annual meeting found the time right after pregnancy is one of the periods in which MS symptoms may not flare back up.

The challenge with translating good science into treatments for patients with multiple sclerosis (MS) is getting the funding to get the trials done, said Rhonda Voskuhl, MD, Jack H. Skirball chair of multiple sclerosis (MS) research, director of the MS program, and professor of neurology at the University of California, Los Angeles (UCLA).

This week, drug maker Celgene resubmitted its New Drug Application (NDA) to the FDA for RPC-1063 (Ozanimod), seeking an indication for the treatment of adults with relapsing multiple sclerosis.

Electronic medical record data on patients with multiple sclerosis is generally consistent with research data and can be used to expand research opportunities, according to a new study.

While the community has seen the first clinical trials and first FDA-approved therapy for pediatric multiple sclerosis, it remains challenging to treat, said Tanuja Chitnis, MD, associate neurologist at Brigham and Women’s Hospital and professor of neurology at Harvard Medical School.

According to findings from a preliminary study, researchers now believe that multiple sclerosis (MS) may not flare following pregnancy as had long been assumed. The study results will be presented at the American Academy of Neurology’s 71st Annual Meeting in Philadelphia, Pennsylvania, May 4-10, 2019.

A recent study sought to determine the impact of flavonoids on fatigue in relapsing and remitting multiple sclerosis (RRMS).

Pediatric multiple sclerosis (MS) represents a small minority of MS diagnoses. WIth symptoms that differ from adults, children with MS often experience delays before they are diagnosed.

Interventions to prevent job loss for patients with multiple sclerosis (MS) should focus on increasing self-efficacy, especially for patients older than 50 years.

A tool at Brigham and Women’s Hospital allows clinicians to view profiles of patients with multiple sclerosis (MS) as a snapshot to better understand their overall disease course, said Tanuja Chitnis, MD, associate neurologist at Brigham and Women’s Hospital and professor of neurology at Harvard Medical School.

According to recently published research, vitamins B12 and B9 can lower levels of homocysteine, improve anemia status, and boost physical health in patients with relapsing remitting multiple sclerosis (MS).

Nearly 10% of drug approvals in 2018 were generic products for branded drugs that had no FDA-approved generics.